• Denileukin diftitox - Wikipedia, the free encyclopedia

    en.wikipedia.org/wiki/Denileukin_diftitox Denileukin diftitox (trade name Ontak) is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 ...
  • Denileukin Diftitox - National Cancer Institute

    www.cancer.gov/about-cancer/treatment/drugs/denileukindiftitox This page contains brief information about denileukin diftitox and a collection of links to more information about the use of this drug, research results, and ongoing ...
  • Denileukin Diftitox - Drug Information - Chemocare

    chemocare.com/chemotherapy/drug-info/denileukin-diftitox.aspx (de-ni-LOO-kin dif-ti-tox) Trade names: Ontak ® Chemocare.com uses generic drug names in all descriptions of drugs. Ontak is the trade name for denileukin diftitox.
    • Denileukin diftitox - Food and Drug Administration

      www.fda.gov/AboutFDA/CentersOffices/.../ucm129218.htm Denileukin diftitox. On October 15, 2008, the U. S. Food and Drug Administration converted the approval of denileukin diftitox (Ontak®, Eisai Medical Research ...
    • Ontak (Denileukin Diftitox) Drug Information: Description ...

      www.rxlist.com/ontak-drug.htm Learn about the prescription medication Ontak (Denileukin Diftitox), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling.
    • denileukin diftitox | Cigna

      www.cigna.com/healthwellness/hw/medications/denileukin-diftitox-d04386a1 What is denileukin diftitox? Denileukin diftitox is a designed protein containing toxins that attach themselves to certain types of malignant cells in the body.
    • Denileukin diftitox | definition of denileukin diftitox by ...

      medical-dictionary.thefreedictionary.com/denileukin+diftitox Denileukin diftitox has been very effective in treating cutaneous lymphoma; it causes rapid tumor lysis by inhibiting protein synthesis in cells that express the ...
    • denileukin diftitox - PharmGKB

      www.pharmgkb.org/chemical/PA164750594 Summary. The FDA-approved drug label for denileukin diftitox (Ontak) notes that it is indicated for patients with persistent or recurrent cutaneous T-cell lymphoma ...
    • FDA Approval for Denileukin Diftitox - National Cancer Institute

      www.cancer.gov/about-cancer/treatment/drugs/fda-denileukindiftitox Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
    • Denileukin Diftitox - Food and Drug Administration

      www.fda.gov/Drugs/ScienceResearch/ResearchAreas/.../ucm301999.htm Drug Link in Drugs@FDA Therapeutic Area HUGO Symbol Referenced Subgroup Labeling Sections with Pharmacogenomic Information; Denileukin Diftitox: Oncology